Fernandes Darren J, Ravenhall Claire E, Harris Trudi, Tran Thai, Vlahos Ross, Stewart Alastair G
Department of Pharmacology, University of Melbourne, Parkville, Victoria 3010, Australia.
Br J Pharmacol. 2004 Aug;142(7):1182-90. doi: 10.1038/sj.bjp.0705809. Epub 2004 Jul 12.
We have investigated the role of p38MAPK in human airway smooth muscle (HASM) proliferation in response to thrombin and bFGF. The regulation of cyclin D1 mRNA, cyclin D1, cyclin E and p21Cip1 protein levels, and the extent of retinoblastoma protein (pRb) phosphorylation in response to activation of p38MAPK have also been examined. Two distinct inhibitors of p38MAPK, SB 203580 (10 microm) and SB 202190 (10 microm), prevented bFGF (0.3-3 nm)-stimulated cell proliferation, but had no effect on the response to thrombin (0.3-3 U ml(-1)). In cells incubated with thrombin or bFGF for 20 h, there was an increase in p38MAPK phosphorylation in response to bFGF, but not to thrombin. Thrombin and bFGF-stimulated increases in ERK phosphorylation and cyclin D1 mRNA and protein levels were not influenced by SB 203580 pre-treatment. Similarly, cyclin E and p21Cip1 protein levels, measured after 20 h incubation with mitogen, did not appear to be regulated by SB 203580 (10 microm). Although both thrombin and bFGF significantly increased levels of pRb phosphorylation, SB 203580 (10 microm) inhibited only bFGF-stimulated pRb phosphorylation. In addition, SB 203580 (10 microm) selectively inhibited bFGF-stimulated DNA synthesis, suggesting that the antimitogenic actions of SB 203580 on pRb phosphorylation cause cell cycle arrest at late G1 phase. In conclusion, these results indicate that p38MAPK is involved in bFGF-, but not in thrombin-stimulated HASM proliferation. The activation of the p38MAPK pathway by bFGF, but not by thrombin, regulates the phosphorylation of pRb without influencing cyclin D1 expression.
我们研究了p38丝裂原活化蛋白激酶(p38MAPK)在人气道平滑肌(HASM)对凝血酶和碱性成纤维细胞生长因子(bFGF)反应中增殖的作用。还检测了细胞周期蛋白D1 mRNA、细胞周期蛋白D1、细胞周期蛋白E和p21Cip1蛋白水平的调节,以及p38MAPK激活后视网膜母细胞瘤蛋白(pRb)的磷酸化程度。两种不同的p38MAPK抑制剂,SB 203580(10微摩尔)和SB 202190(10微摩尔),可阻止bFGF(0.3 - 3纳米)刺激的细胞增殖,但对凝血酶(0.3 - 3单位/毫升)的反应无影响。在用凝血酶或bFGF孵育20小时的细胞中,bFGF可使p38MAPK磷酸化增加,而凝血酶则无此作用。凝血酶和bFGF刺激的细胞外信号调节激酶(ERK)磷酸化及细胞周期蛋白D1 mRNA和蛋白水平的增加不受SB 203580预处理的影响。同样,在用有丝分裂原孵育20小时后检测的细胞周期蛋白E和p21Cip1蛋白水平似乎也不受SB 203580(10微摩尔)的调节。虽然凝血酶和bFGF均显著增加pRb磷酸化水平,但SB 203580(10微摩尔)仅抑制bFGF刺激的pRb磷酸化。此外,SB 203580(10微摩尔)选择性抑制bFGF刺激的DNA合成,提示SB 203580对pRb磷酸化的抗有丝分裂作用导致细胞周期在G1期晚期停滞。总之,这些结果表明p38MAPK参与bFGF刺激的HASM增殖,但不参与凝血酶刺激的增殖。bFGF而非凝血酶激活p38MAPK途径,调节pRb的磷酸化而不影响细胞周期蛋白D1的表达。